Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
1.100
+0.138 (14.38%)
At close: Apr 17, 2026, 4:00 PM EDT
1.090
-0.010 (-0.91%)
After-hours: Apr 17, 2026, 7:58 PM EDT
Senti Biosciences Revenue
In the year 2025, Senti Biosciences had annual revenue of $22.00K. Senti Biosciences had revenue of $22.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$22.00K
Revenue Growth
n/a
P/S Ratio
1,557.22
Revenue / Employee
$647
Employees
34
Market Cap
34.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 2.56M | -1.73M | -40.25% |
| Dec 31, 2022 | 4.29M | 1.53M | 55.23% |
| Dec 31, 2021 | 2.76M | 2.20M | 387.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 8.96M |
| Apollomics | 6.93M |
| Dyadic International | 3.09M |
| Longeveron | 1.20M |
| IGC Pharma | 1.11M |
| ABVC BioPharma | 797.92K |
| Outlook Therapeutics | 205.70K |
SNTI News
- 5 days ago - Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 - GlobeNewsWire
- 17 days ago - Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies - GlobeNewsWire
- 22 days ago - Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 26 days ago - Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference - GlobeNewsWire
- 6 weeks ago - Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development - GlobeNewsWire
- 2 months ago - Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) - GlobeNewsWire